The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.
Patients hospitalized with gram-negative bacteraemia have similar outcomes regardless of whether they receive a 7-day or 14-day course of antibiotic therapy, according to a study presented at ECCMID 2018.
While a 6-day course of flucloxacillin appeared as effective as a 12-day course in curing and reducing short-term risk of relapse among patients hospitalized for cellulitis, the 6-day course led to a greater risk of relapse at 90 days, according to a study from The Netherlands.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.